Analysis
Analysis
Tenax bets the farm on a subgroup
Tenax Therapeutics paused LEVEL-2 enrollment after its Phase 3 miss. It held $118.0M cash at June 30, more than its market value.
The biotech IR desk. Where money meets opportunities. Not investment advice.
Summary. Tenax Therapeutics (TENX) said on August 10, 2026 that its Phase 3 LEVEL trial of oral levosimendan (TNX-103) in pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) missed its primary endpoint. On October 8 it paused enrollment in LEVEL-2 to narrow the entry criteria. The company reported $118.0M of cash at June 30. At the $1.79 close on October 30, its 37.4M common shares were worth about $67M.
When a company with a failed Phase 3 trial is worth less than the cash in its bank account, the market is making a statement. It is not saying the drug is worthless. It is saying it expects the cash to be spent, and does not much trust what it will be spent on. Tenax now has to persuade investors that the second trial, redesigned around a subgroup, deserves the money.
What LEVEL showed
The topline release is candid about the headline. LEVEL randomised 241 patients at 41 sites in the United States and Canada. After 12 weeks, patients on TNX-103 walked 14.0 metres further in six minutes, against 10.4 metres on placebo. That gap was not statistically significant. The key secondary endpoint, a symptom score from the Kansas City Cardiomyopathy Questionnaire, also missed.
The company leans on the rest. In exploratory analyses, NT-proBNP, a blood marker of strain on the heart, fell 49% more on drug than on placebo (nominal p<0.0001). Right ventricular systolic pressure fell by 3.5 mmHg more (nominal p=0.0045). In a prespecified subgroup of patients who walked less than the trial median of 333 metres at baseline, the drug beat placebo by 26.3 metres (95% confidence interval 6.0 to 46.7; nominal p=0.0112). Serious adverse events were balanced between arms.
Stuart Rich, the chief medical officer, said in the release that the trial "enrolled a broad population, including too many patients with less severe disease." Sanjiv Shah of Northwestern University, LEVEL's principal investigator, called the NT-proBNP effect larger than in any prior HFpEF trial and said, in his opinion, the drug is likely to be disease-modifying.
The October pivot
Two months later Tenax told shareholders it would amend LEVEL-2's enrollment criteria to favour the patients LEVEL suggested respond best, and had paused enrollment while sites adopt the new protocol. It has requested a Type C meeting with the FDA on levosimendan's overall development. The 8-K, signed by chief executive Christopher Giordano, gives no date for that meeting or for a resumed readout.
The partner relationship is at least tidy. In June Tenax signed a supply agreement with Orion, the Finnish company that licenses it levosimendan, and pushed the US approval deadline in the licence, past which either side could terminate, to December 31, 2035. That was the sixth amendment to a licence dating from 2013.
The cash
The second-quarter 10-Q shows a net loss of $17.8M for the quarter, up from $10.8M a year earlier, as research spending more than doubled to $12.9M. Management said the June cash, plus money from warrant exercises after the quarter, would fund operations through the second quarter of 2028. That guidance predates the LEVEL result and the LEVEL-2 pause.
Analysis: the case for caution
Our view is that the subgroup is a reasonable hypothesis and a weak foundation. Prespecified or not, a single subgroup with a nominal p-value is the kind of finding that often shrinks when tested on its own. The confidence interval's lower bound of 6 metres is not far from zero. Biomarker effects such as NT-proBNP have a mixed record as predictors of how patients feel or function in heart failure.
Three facts deserve weight. First, the pause costs time, and time costs cash: at the second-quarter net loss of $17.8M, $118.0M covers a little under seven quarters before any rise in trial spending. Second, investors have not yet seen the FDA's reaction, which will decide whether LEVEL-2 as amended can support approval. Third, the company's weighted share count, including pre-funded warrants, reached 50.9M in the second quarter against 39.6M a year earlier, so holders have already absorbed meaningful dilution, and a below-cash valuation makes any further equity raise expensive.
The other side deserves stating. PH-HFpEF has no approved therapy, the biomarker signals were large, and Tenax has enough money to run the next trial without raising soon. Discipline would mean a clear FDA-agreed protocol and a dated readout before the cash is committed.
What to watch
The Type C meeting minutes, the amended LEVEL-2 protocol and any revised runway in the third-quarter 10-Q, which Tenax has not yet filed for the quarter ended September 30.
FAQ
Did Tenax's Phase 3 LEVEL trial succeed? No. It missed the six-minute walk primary endpoint and the key symptom secondary endpoint, per the August 10 release.
Why did Tenax pause LEVEL-2? To amend entry criteria toward patients with more severe disease, per its October 8 8-K.
How much cash does Tenax have? $118.0M at June 30, 2026, per the 10-Q.
Is this investment advice? No. This is analysis of public filings.
Sources: Tenax Therapeutics SEC filings and press releases as linked. Market value uses the October 30, 2026 close and the share count on the 10-Q cover. Not investment advice.
Sources
- missed its primary endpoint
- paused enrollment in LEVEL-2
- $118.0M of cash at June 30
- supply agreement with Orion
Disclosures
- Every figure carries the as-of date of its source.
- This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
- Our method and conflicts policy: aibio.space/disclosures/
aibio.space and its owner hold no position in any stock covered in this report.
As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.
Investor Chat
Loading posts…
aibio